Global Clinical Statistics, Bayer Pharma AG, Berlin, Germany.
Menopause. 2012 Jul;19(7):799-803. doi: 10.1097/gme.0b013e31823de8ba.
The aim of this study was to derive an empirically validated definition of treatment responders for the reduction of moderate to severe hot flushes in postmenopausal women.
This study used prospective blinded data analysis from a placebo-controlled study to investigate the efficacy of a treatment of moderate to severe hot flushes in postmenopausal women. Seven hundred ten postmenopausal women with at least 50 moderate to severe hot flushes per week participated in the study. The participants recorded the number of moderate to severe hot flushes each day in a diary. They also assessed their satisfaction with treatment on a Clinical Global Impression-improvement rating scale. Changes in the weekly number of moderate to severe hot flushes were compared with participants' self-assessments to derive an empirically validated minimal clinically important difference. This anchor-based value was compared with the conventional half-SD rule for minimal clinically important difference in participant-reported outcomes.
Anchor- and distribution-based minimal clinically important differences between "no change/worse" and "minimally improved" were an absolute reduction of 19.1 and 18.6 in the weekly number of moderate to severe hot flushes, respectively. In addition, the threshold between "minimally improved" compared with "much improved or better" was determined, based on the anchor method, as an absolute reduction of 40.3 in the weekly number of moderate to severe hot flushes.
A responder was defined as having at least an improvement of 19.1 hot flushes per week at week 4 and an improvement of 40.3 hot flushes per week at week 12.
本研究旨在为绝经后女性中度至重度热潮红的缓解制定一个经过实证验证的治疗反应者定义。
本研究使用安慰剂对照研究的前瞻性盲数据分析,调查了一种治疗绝经后女性中度至重度热潮红的疗效。710 名每周至少有 50 次中度至重度热潮红的绝经后妇女参加了这项研究。参与者在日记中记录每天中度至重度热潮红的次数。他们还使用临床总体印象改善评定量表评估对治疗的满意度。每周中度至重度热潮红的数量变化与参与者的自我评估进行比较,以得出经过实证验证的最小临床重要差异。该基于锚的价值与参与者报告的结果中最小临床重要差异的传统半标准差规则进行了比较。
基于锚和分布的“无变化/恶化”和“轻度改善”之间的最小临床重要差异分别为每周中度至重度热潮红绝对减少 19.1 和 18.6。此外,基于锚定方法,“轻度改善”与“明显改善或更好”之间的阈值确定为每周中度至重度热潮红绝对减少 40.3。
定义治疗反应者为在第 4 周至少有 19.1 次热潮红改善,在第 12 周至少有 40.3 次热潮红改善。